Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Good Guys, Bad Guys, Guesses, and Near Misses in Nephrology.

Literature DB >> 30559107

Good Guys, Bad Guys, Guesses, and Near Misses in Nephrology.

Abstract

Keywords: Biotechnology; CKD; FGF23; Glucose; Hypoglycemic Agents; Kidney Tubules; Proximal; Renal Insufficiency, Chronic; Research Personnel; SGLT2 inhibitors; SLC5A2 protein; Sodium-Glucose Transporter 2; clinical trials; diuretics; human; nephrology; phosphate

Mesh：

Substances：

Year: 2018 PMID： 30559107 PMCID： PMC6364530 DOI： 10.2215/CJN.13801118

Source DB: PubMed Journal: Clin J Am Soc Nephrol ISSN： 1555-9041 Impact factor: 8.237

× No keyword cloud information.

10 in total

1. SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy: SGLT2 PROTEIN INHIBITION DECREASES RENAL LIPID ACCUMULATION, INFLAMMATION, AND THE DEVELOPMENT OF NEPHROPATHY IN DIABETIC MICE.

Authors: Xiaoxin X Wang; Jonathan Levi; Yuhuan Luo; Komuraiah Myakala; Michal Herman-Edelstein; Liru Qiu; Dong Wang; Yingqiong Peng; Almut Grenz; Scott Lucia; Evgenia Dobrinskikh; Vivette D D'Agati; Hermann Koepsell; Jeffrey B Kopp; Avi Z Rosenberg; Moshe Levi
Journal: J Biol Chem Date: 2017-02-14 Impact factor: 5.157

Review 2. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.

Authors: Hiddo J L Heerspink; Bruce A Perkins; David H Fitchett; Mansoor Husain; David Z I Cherney
Journal: Circulation Date: 2016-07-28 Impact factor: 29.690

3. Effects of Dapagliflozin on Circulating Markers of Phosphate Homeostasis.

Authors: Maarten A de Jong; Sergei I Petrykiv; Gozewijn D Laverman; Antonius E van Herwaarden; Dick de Zeeuw; Stephan J L Bakker; Hiddo J L Heerspink; Martin H de Borst
Journal: Clin J Am Soc Nephrol Date: 2018-12-17 Impact factor: 8.237

4. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors: Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal: N Engl J Med Date: 2015-09-17 Impact factor: 91.245

5. Canagliflozin triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study.

Authors: Jenny E Blau; Viviana Bauman; Ellen M Conway; Paolo Piaggi; Mary F Walter; Elizabeth C Wright; Shanna Bernstein; Amber B Courville; Michael T Collins; Kristina I Rother; Simeon I Taylor
Journal: JCI Insight Date: 2018-04-19

6. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

Authors: Bruce Neal; Vlado Perkovic; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Gordon Law; Mehul Desai; David R Matthews
Journal: N Engl J Med Date: 2017-06-12 Impact factor: 91.245

7. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin.

Authors: Ö Ljunggren; J Bolinder; L Johansson; J Wilding; A M Langkilde; C D Sjöström; J Sugg; S Parikh
Journal: Diabetes Obes Metab Date: 2012-06-29 Impact factor: 6.577

1 in total

Review 1. Potential Safety Issues with Use of Sodium-Glucose Cotransporter 2 Inhibitors, Particularly in People with Type 2 Diabetes and Chronic Kidney Disease.

Authors: Tamara Y Milder; Sophie L Stocker; Richard O Day; Jerry R Greenfield
Journal: Drug Saf Date: 2020-10-23 Impact factor: 5.606